United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 10000 [usp'u] in 10 ml - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity.  there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or ‘‘normal’’ distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction.  in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty.  hcg thus may help predict whether or not orchiopexy will be needed in the future.  although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary.  therapy is usually instituted between the ages four and nine. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulati

Israel - English - Ministry of Health

merck serono ltd - choriogonadotropin alfa - solution for injection - choriogonadotropin alfa 250 mcg / 0.5 ml - choriogonadotropin alfa - choriogonadotropin alfa - - for women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilization (ivf) : ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. - anovulatory or oligo-ovulatory women: ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - choriogonadotropin alfa, quantity: 250 microgram - injection, solution - excipient ingredients: mannitol; water for injections; methionine; dibasic sodium phosphate dihydrate; poloxamer; phosphoric acid; sodium hydroxide; monobasic sodium phosphate monohydrate - ovidrel is indicated in the treatment of (i) women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (ivf): ovidrel is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. (ii) anovulatory or oligo-ovulatory women: ovidrel is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 10000 [usp'u] in 10 ml - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent,

European Union - English - EMA (European Medicines Agency)

merck europe b.v. - choriogonadotropin alfa - anovulation; reproductive techniques, assisted; infertility, female - sex hormones and modulators of the genital system, - ovitrelle is indicated in the treatment of:women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (ivf): ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth;anovulatory or oligo-ovulatory women: ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - choriogonadotropin alfa 250ug; choriogonadotropin alfa 250ug - solution for injection - 250 mcg/0.5ml - active: choriogonadotropin alfa 250ug excipient: mannitol methionine phosphoric acid poloxamer sodium hydroxide water for injection active: choriogonadotropin alfa 250ug excipient: dibasic sodium phosphate dihydrate mannitol methionine phosphoric acid poloxamer sodium hydroxide sodium phosphate water for injection - anovulatory or oligo-ovulatory women: ovidrel is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - choriogonadotropin alfa - injection, solution - 250 mcg - choriogonadotropin alfa 250 mcg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - choriogonadotropin alfa -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - choriogonadotropin alfa - solution for injection - 500microgram/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - human menopausal gonadotrophin, quantity: 1200 iu - injection, solvent for - excipient ingredients: water for injections; metacresol - menopur is indicated for the treatment of infertility in the following clinical situations:,anovulatory infertility, including polycystic ovarian disease (pcod), in women who have been unresponsive to treatment with clomiphene citrate.,controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (art) (e.g. in vitro fertilisation/embryo transfer (ivf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)).